No abstract

Background: Emotion is composed of cognitive processing, physiological response and behavioral reaction. Heart rate variability (HRV) refers to the fluctuations between consecutive heartbeat cycles, and is considered as a non-invasive method for evaluating cardiac autonomic function. HRV analysis plays an important role in emotional study and detection. Objective: In this paper, the physiological foundation of HRV is briefly described, and then the relevant literature relating to HRV-based emotion studies for the performance of HRV in different emotions, emotion recognition, the evaluation of emotional disorders, HRV biofeedback, as well as HRV-based emotion analysis and management enhanced by wearable devices, are reviewed. Significance: It is suggested that HRV is an effective tool for the measurement and regulation of emotional response, with a broad application prospect.

Background: Neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACR) are the standard treatments for esophageal squamous cell carcinoma (ESCC). However, the 5-year overall survival (OS) rate is still far from satisfactory. In recent years, immune checkpoint inhibitors (ICIs) have shown promising results in the treatment of ESCC. More than 20 phase II clinical trials have been launched to explore combinations of ICIs in the neoadjuvant setting for ESCC. Based on our phase II clinical trial, a two-arm phase III trial was launched in Henan Cancer Hospital. ICIs combined with NAC may usher in a new era and may benefit locally advanced, resectable ESCC patients.Methods: A two-arm phase III trial was launched in April 2020 in Henan Cancer Hospital. Patient recruitment will be completed within 18 months. The primary endpoint is event-free survival (EFS).The secondary endpoints include pathologic complete response (pCR), disease-free survival (DFS) rate, overall response rate (ORR), R0 resection rate, major pathologic response (MPR), adverse events (AEs), complication rate and quality of life (QOL). A biobank of pretreatment, resected tumor tissue and paired blood samples will be built for translational research in the future.Discussion: This RCT directly compares NAC with neoadjuvant toripalimab plus chemotherapy in terms of EFS for locally advanced ESCC. The results may usher in a new era of resectable ESCC treatment.

No abstract

No abstract